Filters

Clear all

Expert Opinion

Plain Language Summary

Expert Review

Text Availability

Abstract

Full text

Free full text

Publication Types

Journal Article

Research Support, Non-U.S. Gov't

Observational Study

Randomized Controlled Trial

Multicenter Study

Clinical Trial, Phase III

Review

Comparative Study

Clinical Trial

Letter

Case Reports

Clinical Trial, Phase I

Equivalence Trial

Publication Year

From

Quick links

Individual year

2022

2021

2020

2019

2018

2017

2014

Sort by:

selected

Print page

Email selected articles

Favourite selected articles

Create a NED Search Alert for this search

Save this search

Advanced Search

Run an advanced search

Results for
""Cobicistat""[mesh_terms]

27 Results

Searching titles within these results

Efficacy and safety of co-formulated elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in HIV-positive patients: real-world data.

Fehmi Tabak, Esra Zerdali, Ozlem Altuntaş, Alper Gunduz, Sibel Bolukcu, Bilgul Mete, Inci Y Nakir, Hayat Kumbasar Karaosmanoglu, Dilek S Yildiz, Meliha Meric Koc, İlyas Dokmetas

International journal of STD & AIDS 2021;32(6):562-569

Full Text

Abstract

Genvoya-Associated and Simvastatin-Associated Noninflammatory and Nonautoimmune Myopathy: A Case Report and Literature Review.

Merry Huang, Richard A Prayson, Yuebing Li

Journal of clinical neuromuscular disease 2022;24(2):75-79

Full Text

Abstract

Week 96 subgroup analyses of the phase 3, randomized AMBER and EMERALD trials evaluating the efficacy and safety of the once daily darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) single-tablet regimen in antiretroviral treatment (ART)-naïve and -experienced, virologically-suppressed adults living with HIV-1.

Gregory D Huhn, Aimee Wilkin, Cristina Mussini, Christoph D Spinner, John Jezorwski, Mohsine El Ghazi, Erika Van Landuyt, Erkki Lathouwers, Kimberley Brown, Bryan Baugh

HIV research & clinical practice 2022;21(6):151-167

Free Full Text

Abstract

Combining SJ733, an oral ATP4 inhibitor of Plasmodium falciparum, with the pharmacokinetic enhancer cobicistat: An innovative approach in antimalarial drug development.

Aditya H Gaur, John C Panetta, Amber M Smith, Ronald H Dallas, Burgess B Freeman, Tracy B Stewart, Li Tang, Elizabeth John, Kristen C Branum, Nehali D Patel, Shelley Ost, Ryan N Heine, Julie L Richardson, Jared T Hammill, Lidiya Bebrevska, Fabian Gusovsky, Noritsugu Maki, Toshiharu Yanagi, Patricia M Flynn, James S McCarthy, Stephan Chalon, R Kiplin Guy

EBioMedicine 2022;80():104065

Free Full Text

Abstract

A phase IV, open-label three-arm study investigating the impact of a combination of tenofovir disoproxil fumarate/emtricitabine with raltegravir or dolutegravir or elvitegravir/cobicistat on renal function in HIV-1 antiretroviral naïve patients.

Margherita Bracchi, Nicole Pagani, Alessia Dalla Pria, Ana Milinkovic, Nneka Nwokolo, Lervina Thomas, Sundhyia Mandalia, Marta Boffito, Graeme Moyle

HIV research & clinical practice 2022;22(5):128-139

Full Text

Abstract

Brief Report: Randomized, Double-Blind Comparison of Tenofovir Alafenamide (TAF) vs Tenofovir Disoproxil Fumarate (TDF), Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine (E/C/F) for Initial HIV-1 Treatment: Week 144 Results.

José R Arribas, Melanie Thompson, Paul E Sax, Bernhard Haas, Cheryl McDonald, David A Wohl, Edwin DeJesus, Amanda E Clarke, Susan Guo, Hui Wang, Christian Callebaut, Andrew Plummer, Andrew Cheng, Moupali Das, Scott McCallister

Journal of acquired immune deficiency syndromes (1999) 2017;75(2):211-218

Full Text

Abstract

How relevant are the drug-drug interactions between antiretroviral boosted-based regimens and calcium channel blockers in real life?

Dario Cattaneo, Tiziana Formenti, Noemi Astuti, Paola Meraviglia, Annalisa Ridolfo, Cristina Gervasoni

The Journal of antimicrobial chemotherapy 2019;73(8):2271-2273

Full Text

Effectiveness of Switching to Darunavir/Cobicistat in Virologically Suppressed HIV-Positive Patients Receiving Ritonavir-Boosted Protease Inhibitor-Based Regimen: The "STORE" Study.

Andrea Gori, Andrea Antinori, Alessandra Vergori, Maria Vittoria Cossu, Barbara Menzaghi, Gaetana Sterrantino, Stefano Rusconi, Anna Maria Cattelan, Francesco Castelli, Nicola Gianotti, Giancarlo Orofino, Diego Ripamonti, Stefano Savinelli, Elio Manzillo, Teresa Antonia Santantonio, Benedetto Maurizio Celesia, Roberto Cauda, Renato Maserati, Antonella d'Arminio Monforte, Christof Stingone, Stefano Bonora, Alessia Uglietti, Roberta Termini, Francesco Rucci, Daniela Mancusi

Journal of acquired immune deficiency syndromes (1999) 2021;84(3):290-294

Free Full Text

Abstract

Darunavir-cobicistat-emtricitabine-tenofovir alafenamide: safety and efficacy of a protease inhibitor in the modern era.

Nicola Squillace, Giorgio Bozzi, Elisa Colella, Andrea Gori, Alessandra Bandera

Drug design, development and therapy 2019;12():3635-3643

Free Full Text

Abstract

Positioning of darunavir/cobicistat-containing antiretroviral regimens in real life: results from a large multicentre observational prospective cohort (SCOLTA).

Giordano Madeddu, Lucia Taramasso, Elena Ricci, Antonio Cascio, Laura Valsecchi, Barbara Menzaghi, Nicola Squillace, Paolo Maggi, Giuseppe Vittorio De Socio, Chiara Dentone, Giovanni F Pellicanò, Leonardo Calza, Goffredo Angioni, Paolo Bonfanti, Antonio Di Biagio

AIDS research and therapy 2020;16(1):21

Free Full Text

Abstract

How recent findings on the pharmacokinetics and pharmacodynamics of integrase inhibitors can inform clinical use.

Emilie Elliot, Mimie Chirwa, Marta Boffito

Current opinion in infectious diseases 2018;30(1):58-73

Full Text

Abstract

Brief Report: Pharmacokinetics of Crushed Elvitegravir Combination Tablet Given With or Without Enteral Nutrition.

Mieke Jongbloed-de Hoon, Angela Colbers, Kirsten Velthoven-Graafland, Marjolijn Duisenberg-van Essenberg, Martine Kruijssen, Evertine Abbink, Reinout van Crevel, David Burger

Journal of acquired immune deficiency syndromes (1999) 2017;74(5):571-574

Full Text

Abstract

Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial.

Chloe Orkin, Jean-Michel Molina, Eugenia Negredo, José R Arribas, Joseph Gathe, Joseph J Eron, Erika Van Landuyt, Erkki Lathouwers, Veerle Hufkens, Romana Petrovic, Simon Vanveggel, Magda Opsomer

The lancet. HIV 2018;5(1):e23-e34

Full Text

Abstract

Bone mineral density in virologically suppressed people aged 60 years or older with HIV-1 switching from a regimen containing tenofovir disoproxil fumarate to an elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide single-tablet regimen: a multicentre, open-label, phase 3b, randomised trial.

Franco Maggiolo, Giuliano Rizzardini, François Raffi, Federico Pulido, Maria Gracia Mateo-Garcia, Jean-Michel Molina, Edmund Ong, Yongwu Shao, David Piontkowsky, Moupali Das, Ian McNicholl, Richard Haubrich

The lancet. HIV 2020;6(10):e655-e666

Full Text

Abstract

Weight gain and dyslipidemia among virally suppressed HIV-positive patients switching to co-formulated elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide.

Po-Hsien Kuo, Hsin-Yun Sun, Yu-Chung Chuang, Pei-Ying Wu, Wen-Chun Liu, Chien-Ching Hung

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2020;92():71-77

Free Full Text

Abstract

Results: 1 – 15 / 27

Filters

Expert Opinion

Text Availability

Publication Types

Publication Year

Results for ""Cobicistat""[mesh_terms]

Efficacy and safety of co-formulated elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in HIV-positive patients: real-world data.

Genvoya-Associated and Simvastatin-Associated Noninflammatory and Nonautoimmune Myopathy: A Case Report and Literature Review.

Combining SJ733, an oral ATP4 inhibitor of Plasmodium falciparum, with the pharmacokinetic enhancer cobicistat: An innovative approach in antimalarial drug development.

A phase IV, open-label three-arm study investigating the impact of a combination of tenofovir disoproxil fumarate/emtricitabine with raltegravir or dolutegravir or elvitegravir/cobicistat on renal function in HIV-1 antiretroviral naïve patients.

Brief Report: Randomized, Double-Blind Comparison of Tenofovir Alafenamide (TAF) vs Tenofovir Disoproxil Fumarate (TDF), Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine (E/C/F) for Initial HIV-1 Treatment: Week 144 Results.

How relevant are the drug-drug interactions between antiretroviral boosted-based regimens and calcium channel blockers in real life?

Effectiveness of Switching to Darunavir/Cobicistat in Virologically Suppressed HIV-Positive Patients Receiving Ritonavir-Boosted Protease Inhibitor-Based Regimen: The "STORE" Study.

Darunavir-cobicistat-emtricitabine-tenofovir alafenamide: safety and efficacy of a protease inhibitor in the modern era.

Positioning of darunavir/cobicistat-containing antiretroviral regimens in real life: results from a large multicentre observational prospective cohort (SCOLTA).

How recent findings on the pharmacokinetics and pharmacodynamics of integrase inhibitors can inform clinical use.

Brief Report: Pharmacokinetics of Crushed Elvitegravir Combination Tablet Given With or Without Enteral Nutrition.

Weight gain and dyslipidemia among virally suppressed HIV-positive patients switching to co-formulated elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide.

Results for
""Cobicistat""[mesh_terms]